摘要
文迪雅事件背后的讨论异常激烈,隐瞒不利的试验结果、投票专家与相关药厂存在利益纠葛等说法都不乏支持者,然而,比起辨明是非,如何将自身损失降至最低点,重塑企业在业内和医患面前的良好形象可能更考究当事企业。
The debate behind Avandia hearing is extremely fierce---the manufacturer had concealed the unfavorable trial outcomes,or the voting experts had gotten financial benefits from the manufacturer? However,compared with distinguishing right from wrong,how to minimize the losses,and how to reshape the good image of the manufacturer are more severe tests for the manufacturer.
出处
《中国处方药》
2010年第7期12-12,共1页
Journal of China Prescription Drug
